Sarepta Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|
| Revenue | $154.6M | $5.4M | $1.3M | $9.8M |
| Cost of Revenue | — | $130.0K | — | — |
| Gross Profit | — | $5.3M | — | — |
| Gross Margin | — | 97.6% | — | — |
| Operating Expenses | ||||
| Research & Development | $166.7M | $188.3M | $146.4M | $94.2M |
| SG&A Expense | $122.7M | $83.7M | $75.0M | $49.3M |
| Operating Income | $-171.6M | $-266.7M | $-220.2M | $-133.8M |
| Operating Margin | -111.0% | -4,920.3% | -17,572.5% | -1,371.2% |
| Interest Expense | $5.8M | $1.9M | $1.4M | $100.0K |
| Pretax Income | $-48.6M | $-267.3M | $-220.0M | — |
| Income Tax Expense | $2.1M | — | — | — |
| Net Income | $-50.7M | $-267.3M | $-220.0M | $-135.8M |
| Net Margin | -32.8% | -4,930.2% | -17,560.3% | -1,391.7% |
| EPS (Basic) | $-0.86 | $-5.49 | $-5.20 | $-3.39 |
| EPS (Diluted) | $-0.86 | $-5.49 | $-5.20 | $-3.39 |
| Shares Outstanding (Basic) | 58.8M | 48.7M | 42.3M | 40.0M |
| Shares Outstanding (Diluted) | 58.8M | 48.7M | 42.3M | 40.0M |
| Dividends Per Share | — | — | — | — |